NASDAQ:EMMA

As of July 17, 2019, MYnd Analytics, Inc. was acquired by Emmaus Life Sciences, Inc., in a reverse merger transaction. MYnd Analytics, Inc. operates as a predictive analytics company primarily in the United States. The company manages the delivery of telepsychiatry and telebehavioral health services through a network of psychiatrists, psychologists, and therapists. The company is commercializing its psychiatric electroencephalogram (EEG) evaluation registry predictive analytics tool to help physicians reduce trial and error treatment in mental health. Its technology platform utilizes complex algorithms to analyze EEGs to generate psychiatric EEG evaluation registry reports to predict individual responses to a range of medications prescribed for the treatment of behavioral disorders, including depression, anxiety, bipolar disorder, post-traumatic stress disorder sand other non-psychotic disorders. The company was formerly known as CNS Response, Inc. and changed its name to MYnd Analytics, Inc. in November 2015. MYnd Analytics, Inc. was founded in 2000 and is headquartered in Mission Viejo, California.